

# PRODUCT INFORMATION



## LEE011 (succinate)

Item No. 36414

**CAS Registry No.:** 1374639-75-4  
**Formal Name:** butanedioic acid, compd. with  
7-cyclopentyl-N,N-dimethyl-2-[[5-(1-  
piperazinyl)-2-pyridinyl]amino]-7H-  
pyrrolo[2,3-d]pyrimidine-6-carboxamide

**Synonyms:** NVP-LEE011, Ribociclib

**MF:** C<sub>23</sub>H<sub>30</sub>N<sub>8</sub>O • C<sub>4</sub>H<sub>6</sub>O<sub>4</sub>

**FW:** 552.6


**Purity:** ≥98%

**UV/Vis.:** λ<sub>max</sub>: 276, 345 nm

**Supplied as:** A solid

**Storage:** -20°C

**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

LEE011 (succinate) is supplied as a solid. A stock solution may be made by dissolving the LEE011 (succinate) in the solvent of choice, which should be purged with an inert gas. LEE011 (succinate) is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of LEE011 (succinate) in these solvents is approximately 5 mg/ml.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of LEE011 (succinate) can be prepared by directly dissolving the solid in aqueous buffers. The solubility of LEE011 (succinate) in PBS (pH 7.2) is approximately 10 mg/ml. We do not recommend storing the aqueous solution for more than one day.

### Description

LEE011 is a cyclin-dependent kinase 4 (Cdk4) and Cdk6 inhibitor (IC<sub>50</sub>s = 0.53 and 2.3 nM, respectively).<sup>1</sup> It is selective for Cdk4/6 over Cdk1, Cdk2, Cdk5, Cdk7, and Cdk9 (IC<sub>50</sub>s = >1,400, >2,500, >2,000, >2,000, and 190 nM, respectively). LEE011 reduces the proliferation of MCF-7 and T47D breast cancer cells (IC<sub>50</sub>s = 200 and 260 nM, respectively). It induces cell death in C666-1 and NPC/HK1 nasopharyngeal carcinoma cells (IC<sub>50</sub>s = 12.25 and 5.07 μM, respectively) and cell cycle arrest at the G<sub>0</sub>/G<sub>1</sub> phase in the same cells when used at a concentration of 10 μM.<sup>2</sup> LEE011 (200 mg/kg every two weeks), in combination with the PI3Kα inhibitor alpelisib (BYL719; Item No. 16986), reduces tumor growth in two patient-derived xenograft (PDX) mouse models of nasopharyngeal carcinoma.

### References

1. Chen, P., Lee, N.V., Hu, W., *et al.* Spectrum and degree of CDK drug interactions predicts clinical performance. *Mol. Cancer Ther.* **15**(10), 2273-2281 (2016).
2. Wong, C.-H., Ma, B.B.Y., Hui, C.W.C., *et al.* Preclinical evaluation of ribociclib and its synergistic effect in combination with alpelisib in non-keratinizing nasopharyngeal carcinoma. *Sci. Rep.* **8**(1), 8010 (2018).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 06/08/2023

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM